Stockscreener 앱 받기
3.79
5.01%
-0.20
시간 외 거래:
3.80
0.010
+0.26%
Lantern Pharma Inc 주식(LTRN)의 최신 뉴스
What drives Lantern Pharma Inc. stock priceFast-track wealth growth - Autocar Professional
What analysts say about Lantern Pharma Inc. stockFastest-growing stock picks - Autocar Professional
Lantern Pharma secures EU patent for AI-driven cancer drug LP-284 - MSN
Lantern Pharma Secures EU Patent Allowance for LP-284, Bolstering Global IP Position for AI-Developed Cancer Therapy - BioSpace
Lantern Pharma (LTRN) Secures EU Patent for Cancer Drug LP-284 - GuruFocus
Lantern Pharma (LTRN) Gains Patent Approval for Key Drug in Euro - GuruFocus
Is Lantern Pharma Inc. a good long term investmentHigh-velocity capital appreciation - Autocar Professional
Lantern Pharma Inc. Stock Analysis and ForecastPhenomenal returns - jammulinksnews.com
Lantern Pharma Unveils AI Module for Predicting Cancer Treatment Efficacy - AInvest
Lantern Pharma (NASDAQ: LTRN) Launches AI Module to Accelerate Development of Targeted Cancer Combination Therapies - The Globe and Mail
IBN Initiates Coverage of Lantern Pharma Inc. - GlobeNewswire
Lantern Pharma Initiates Coverage with IBN, Aims to Revolutionize Oncology Drug Development - AInvest
Why Lantern Pharma Inc. stock attracts strong analyst attentionFree Stock Movement Tracking - Newser
How Lantern Pharma Inc. stock performs during market volatilityInvestor Friendly Risk Reward - Newser
Lantern Pharma Inc. Unveils AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer Treatment - MarketScreener
Lantern Pharma launches AI module to predict cancer treatment combos By Investing.com - Investing.com India
Lantern Pharma (LTRN) Launches AI Module for Cancer Treatment Ad - GuruFocus
Lantern Pharma launches AI module to predict cancer treatment combos - Investing.com Australia
Lantern Pharma Unveils Groundbreaking AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer Treatment - Business Wire
What makes Lantern Pharma Inc. stock price move sharplyFree Access to Community - Newser
LTRN Stock Price and Chart — NASDAQ:LTRN - TradingView
Lantern Pharma Enters ATM Sales Agreement with ThinkEquity - TipRanks
Why Lantern Pharma (NASDAQ: LTRN) Is ‘One to Watch’ - The Globe and Mail
Why Lantern Pharma (NASDAQ: LTRN) Is ‘One To Watch’ - Barchart.com
Lantern Pharma Inc. Harnesses AI to Revolutionize Oncology Drug Development - citybuzz -
Lantern Pharma’s (NASDAQ: LTRN) AI-Powered Platform Delivers Promising and Durable Results in Lung Cancer Trial - Barchart.com
Lantern Pharma (NASDAQ: LTRN) Reports Complete Response in Advanced NSCLC Patient in HARMONIC(TM) Trial - The Globe and Mail
Lantern Pharma Inc. Reports Complete Response in Advanced NSCLC Patient in HARMONIC(TM) Trial - citybuzz -
Lung Cancer Patient in Lantern Pharma's Harmonic Trial Shows Durable Complete Response in Target Cancer Lesions with Survival Continuing for Nearly Two Years | LTRN Stock News - GuruFocus
Lung Cancer Patient In Lantern Pharma's Harmonic Trial Shows Durable Complete Response In Target Cancer Lesions With Survival Continuing For Nearly Two Years - MarketScreener
Lung Cancer Patient in Lantern Pharma’s Harmonic Trial Shows Durable Complete Response in Target Cancer Lesions with Survival Continuing for Nearly Two Years - Yahoo Finance
PRN_FinancialWrapper - FinancialContent
Two Sigma Investments LP Sells 17,795 Shares of Lantern Pharma Inc. (NASDAQ:LTRN) - Defense World
Lantern Pharma shares sold by major shareholder for $123,600 - Investing.com South Africa
Lantern Pharma Inc. (NASDAQ:LTRN) Q1 2025 Earnings Call Transcript - MSN
Lantern Pharma sees $208,271 in stock sales by major shareholders - Investing.com
Lantern Pharma (NASDAQ:LTRN) Trading Down 4.4% – Here’s Why - Defense World
0.87%
0.17%
자본화:
|
볼륨(24시간):